Patents by Inventor Caretha L. Creasy

Caretha L. Creasy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170348306
    Abstract: This invention relates to methods of treating cancer in a subject in need thereof, e.g.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Inventors: Caretha L. CREASY, Gopinath GANJI, Michael T. MCCABE, Kimberly N. SMITHEMAN
  • Patent number: 9730925
    Abstract: This invention relates to methods of treating cancer in a subject such as a human and determining at least one of the following in a sample from the subject, such as a human: (a) the presence or absence of a mutation at the alanine 677 (A677) residue in EZH2; or (b) the presence or absence of a mutation at the tyrosine 641 (Y641) residue in EZH2; or (c) the presence or absence of an increased level of H3K27me3 as compared to a control, and administering to said human an effective amount of an EZH2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of the A677 mutation, Y641 mutation, or increased level of H3K27me3 is present in the sample.
    Type: Grant
    Filed: September 30, 2012
    Date of Patent: August 15, 2017
    Assignee: GLAXOMITHKLINE LLC
    Inventors: Caretha L. Creasy, Gopinath Ganji, Michael T McCabe, Kimberly N. Smitheman
  • Publication number: 20170105997
    Abstract: Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using EZH2 inhibitors in human populations having a translocation MMSET or a decreased level of a functional UTX protein or both.
    Type: Application
    Filed: March 21, 2015
    Publication date: April 20, 2017
    Inventors: Caretha L. CREASY, Jonathan LIGHT, Michael McCABE, Relja POPOVIC
  • Publication number: 20150313906
    Abstract: The present invention relates to a method of treating cancer and pre-cancerous syndromes in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering: (i) an EZH2 inhibitor selected from: N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide, or a pharmaceutically acceptable salt thereof 1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pryidinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide, or a pharmaceutically acceptable salt thereof and N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide, or a pharmaceutically acceptable salt thereof and (ii) a Bcl-2 inhibitor, to a human in need thereof.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 5, 2015
    Inventors: Caretha L. CREASY, Ari M. MELNICK, Michael T. MCCABE
  • Publication number: 20140378470
    Abstract: This invention relates to methods of treating cancer in a subject such as a human and determining at least one of the following in a sample from the subject, such as a human: (a) the presence or absence of a mutation at the alanine 677 (A677) residue in EZH2; or (b) the presence or absence of a mutation at the tyrosine 641 (Y641) residue in EZH2; or (c) the presence or absence of an increased level of H3K27me3 as compared to a control, and administering to said human an effective amount of an EZH2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of the A677 mutation, Y641 mutation, or increased level of H3K27me3 is present in the sample.
    Type: Application
    Filed: September 30, 2012
    Publication date: December 25, 2014
    Inventors: Caretha L. Creasy, Gopinath Ganji, Michael T. McCabe, Kimberly N. Smitheman
  • Publication number: 20020064852
    Abstract: Mus Musculus mDYRK2 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus Musculus mDYRK2.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 30, 2002
    Applicant: SmithKline Beecham Corporation/SmithKline Beecham plc.
    Inventors: Caretha L. Creasy, Brian M. Burns
  • Patent number: 6165766
    Abstract: hYAK3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: December 26, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Caretha L. Creasy, Wei Xie
  • Patent number: 6159716
    Abstract: hYAK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 12, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Caretha L. Creasy, George P. Livi, Damien J. Dunnington, Usman Shabon
  • Patent number: 5972606
    Abstract: hYAK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: October 26, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Caretha L. Creasy, George P. Livi, Damien J. Dunnington, Usman Shabon
  • Patent number: 5965420
    Abstract: hYAK3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: October 12, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Caretha L. Creasy, Wei Xie